share_log

基石藥業-B：截至二零二三年十二月三十一日止年度年度業績公告

CSTONE PHARMA-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023

香港交易所 ·  Mar 27 08:43
Summary by Moomoo AI
基石藥業-B（「本公司」）公布截至2023年12月31日止年度業績，總收入為人民幣463.8百萬元，較去年同期減少3.6%。其中，藥品銷售收入為人民幣336.7百萬元，授權費收入及特許權使用費收入同比增加8.6%，至人民幣127.1百萬元。研發開支較去年同期減少人民幣86.4百萬元，至人民幣527.8百萬元，主要由於里程碑費用及第三方合約成本以及僱員成本降低。行政開支亦減少至人民幣182.7百萬元。年內虧損為人民幣367.2百萬元，較去年減少59.3%。本公司於報告期間無派發股息，並無涉及任何重大訴訟或仲裁。
基石藥業-B（「本公司」）公布截至2023年12月31日止年度業績，總收入為人民幣463.8百萬元，較去年同期減少3.6%。其中，藥品銷售收入為人民幣336.7百萬元，授權費收入及特許權使用費收入同比增加8.6%，至人民幣127.1百萬元。研發開支較去年同期減少人民幣86.4百萬元，至人民幣527.8百萬元，主要由於里程碑費用及第三方合約成本以及僱員成本降低。行政開支亦減少至人民幣182.7百萬元。年內虧損為人民幣367.2百萬元，較去年減少59.3%。本公司於報告期間無派發股息，並無涉及任何重大訴訟或仲裁。
KEYSTONE PHARMACEUTICAL-B (THE “COMPANY”) ANNOUNCED ITS RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023 WITH A TOTAL REVENUE OF RMB463.8 MILLION, A DECREASE OF 3.6% COMPARED TO THE SAME PERIOD LAST YEAR. Among them, pharmaceutical sales revenue was RMB336.7 million, and license fee revenue and royalty fee revenue increased 8.6% year-over-year to RMB127.1 million. R&D expenses decreased by RMB86.4 million to RMB527.8 million from the same period last year, mainly due to lower milestone fees and third-party contract costs and employee costs. Administrative expenses were also reduced to RMB182.7 million. The loss for the year amounted to RMB367.2 million, a decrease of 59.3% from last year. The Company did not distribute dividends during the reporting period and was not involved in any significant litigation or arbitration.
KEYSTONE PHARMACEUTICAL-B (THE “COMPANY”) ANNOUNCED ITS RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023 WITH A TOTAL REVENUE OF RMB463.8 MILLION, A DECREASE OF 3.6% COMPARED TO THE SAME PERIOD LAST YEAR. Among them, pharmaceutical sales revenue was RMB336.7 million, and license fee revenue and royalty fee revenue increased 8.6% year-over-year to RMB127.1 million. R&D expenses decreased by RMB86.4 million to RMB527.8 million from the same period last year, mainly due to lower milestone fees and third-party contract costs and employee costs. Administrative expenses were also reduced to RMB182.7 million. The loss for the year amounted to RMB367.2 million, a decrease of 59.3% from last year. The Company did not distribute dividends during the reporting period and was not involved in any significant litigation or arbitration.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more